Stab1 and Stab2 single inhibition mediates beneficial effects in atherosclerosis development (Manta et al., 2022), anti‐Stab1 inhibition is in clinical trials in immune‐oncology (Virtakoivu et al., 2021). Here, STAB1 is linked to atherosclerosis.